vs
Side-by-side financial comparison of Hologic (HOLX) and WEIBO Corp (WB). Click either name above to swap in a different company.
WEIBO Corp is the larger business by last-quarter revenue ($1.3B vs $1.0B, roughly 1.2× Hologic). WEIBO Corp runs the higher net margin — 35.7% vs 17.1%, a 18.6% gap on every dollar of revenue. Over the past eight quarters, WEIBO Corp's revenue compounded faster (22.6% CAGR vs 1.5%).
Hologic, Inc. is an American medical technology company primarily focused on women's health; it sells medical devices for diagnostics, surgery, and medical imaging.
Weibo Corporation is a Chinese social network company known for the microblogging website Sina Weibo. It is based in Beijing, China.
HOLX vs WB — Head-to-Head
Income Statement — Q1 FY2026 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.0B | $1.3B |
| Net Profit | $179.1M | $458.3M |
| Gross Margin | 56.0% | — |
| Operating Margin | 22.6% | 29.1% |
| Net Margin | 17.1% | 35.7% |
| Revenue YoY | 2.5% | — |
| Net Profit YoY | -10.9% | — |
| EPS (diluted) | $0.79 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.0B | — | ||
| Q3 25 | $1.0B | $1.3B | ||
| Q2 25 | $1.0B | $841.7M | ||
| Q1 25 | $1.0B | $396.9M | ||
| Q4 24 | $1.0B | — | ||
| Q3 24 | $988.0M | $1.3B | ||
| Q2 24 | $1.0B | $833.4M | ||
| Q1 24 | $1.0B | $395.5M |
| Q4 25 | $179.1M | — | ||
| Q3 25 | $187.2M | $458.3M | ||
| Q2 25 | $194.9M | $234.8M | ||
| Q1 25 | $-17.4M | $108.1M | ||
| Q4 24 | $201.0M | — | ||
| Q3 24 | $178.6M | $297.4M | ||
| Q2 24 | $194.5M | $164.6M | ||
| Q1 24 | $169.9M | $51.1M |
| Q4 25 | 56.0% | — | ||
| Q3 25 | 55.6% | — | ||
| Q2 25 | 56.3% | — | ||
| Q1 25 | 37.5% | — | ||
| Q4 24 | 56.8% | — | ||
| Q3 24 | 56.4% | — | ||
| Q2 24 | 55.4% | — | ||
| Q1 24 | 53.3% | — |
| Q4 25 | 22.6% | — | ||
| Q3 25 | 22.6% | 29.1% | ||
| Q2 25 | 24.9% | 30.4% | ||
| Q1 25 | -0.7% | 27.8% | ||
| Q4 24 | 22.5% | — | ||
| Q3 24 | 23.3% | 29.0% | ||
| Q2 24 | 24.1% | 28.2% | ||
| Q1 24 | 20.7% | 25.2% |
| Q4 25 | 17.1% | — | ||
| Q3 25 | 17.8% | 35.7% | ||
| Q2 25 | 19.0% | 27.9% | ||
| Q1 25 | -1.7% | 27.2% | ||
| Q4 24 | 19.7% | — | ||
| Q3 24 | 18.1% | 22.9% | ||
| Q2 24 | 19.2% | 19.8% | ||
| Q1 24 | 16.7% | 12.9% |
| Q4 25 | $0.79 | — | ||
| Q3 25 | $0.84 | — | ||
| Q2 25 | $0.86 | — | ||
| Q1 25 | $-0.08 | — | ||
| Q4 24 | $0.87 | — | ||
| Q3 24 | $0.75 | — | ||
| Q2 24 | $0.82 | — | ||
| Q1 24 | $0.72 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $2.4B | $1.1B |
| Total DebtLower is stronger | $2.5B | — |
| Stockholders' EquityBook value | $5.2B | $3.9B |
| Total Assets | $9.2B | $6.9B |
| Debt / EquityLower = less leverage | 0.48× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.4B | — | ||
| Q3 25 | $2.2B | $1.1B | ||
| Q2 25 | $1.9B | $1.2B | ||
| Q1 25 | $1.6B | $1.2B | ||
| Q4 24 | $2.0B | — | ||
| Q3 24 | $2.3B | — | ||
| Q2 24 | $2.4B | $1.9B | ||
| Q1 24 | $2.2B | $2.1B |
| Q4 25 | $2.5B | — | ||
| Q3 25 | $2.5B | — | ||
| Q2 25 | $2.5B | — | ||
| Q1 25 | $2.5B | — | ||
| Q4 24 | $2.5B | — | ||
| Q3 24 | $2.5B | — | ||
| Q2 24 | $2.5B | — | ||
| Q1 24 | $2.6B | — |
| Q4 25 | $5.2B | — | ||
| Q3 25 | $5.0B | $3.9B | ||
| Q2 25 | $4.8B | $3.6B | ||
| Q1 25 | $4.6B | $3.5B | ||
| Q4 24 | $4.8B | — | ||
| Q3 24 | $5.1B | — | ||
| Q2 24 | $5.0B | $3.4B | ||
| Q1 24 | $4.8B | $3.3B |
| Q4 25 | $9.2B | — | ||
| Q3 25 | $9.0B | $6.9B | ||
| Q2 25 | $8.8B | $6.5B | ||
| Q1 25 | $8.5B | $6.7B | ||
| Q4 24 | $8.7B | — | ||
| Q3 24 | $9.2B | — | ||
| Q2 24 | $8.9B | $7.1B | ||
| Q1 24 | $8.7B | $7.3B |
| Q4 25 | 0.48× | — | ||
| Q3 25 | 0.50× | — | ||
| Q2 25 | 0.52× | — | ||
| Q1 25 | 0.55× | — | ||
| Q4 24 | 0.53× | — | ||
| Q3 24 | 0.49× | — | ||
| Q2 24 | 0.51× | — | ||
| Q1 24 | 0.53× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $229.9M | — |
| Free Cash FlowOCF − Capex | $215.2M | — |
| FCF MarginFCF / Revenue | 20.5% | — |
| Capex IntensityCapex / Revenue | 1.4% | — |
| Cash ConversionOCF / Net Profit | 1.28× | — |
| TTM Free Cash FlowTrailing 4 quarters | $1.0B | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $229.9M | — | ||
| Q3 25 | $355.1M | — | ||
| Q2 25 | $343.3M | — | ||
| Q1 25 | $169.4M | — | ||
| Q4 24 | $189.3M | — | ||
| Q3 24 | $367.0M | — | ||
| Q2 24 | $405.8M | — | ||
| Q1 24 | $292.4M | — |
| Q4 25 | $215.2M | — | ||
| Q3 25 | $341.4M | — | ||
| Q2 25 | $330.5M | — | ||
| Q1 25 | $153.9M | — | ||
| Q4 24 | $172.5M | — | ||
| Q3 24 | $350.6M | — | ||
| Q2 24 | $385.3M | — | ||
| Q1 24 | $279.6M | — |
| Q4 25 | 20.5% | — | ||
| Q3 25 | 32.5% | — | ||
| Q2 25 | 32.3% | — | ||
| Q1 25 | 15.3% | — | ||
| Q4 24 | 16.9% | — | ||
| Q3 24 | 35.5% | — | ||
| Q2 24 | 38.1% | — | ||
| Q1 24 | 27.5% | — |
| Q4 25 | 1.4% | — | ||
| Q3 25 | 1.3% | — | ||
| Q2 25 | 1.3% | — | ||
| Q1 25 | 1.5% | — | ||
| Q4 24 | 1.6% | — | ||
| Q3 24 | 1.7% | — | ||
| Q2 24 | 2.0% | — | ||
| Q1 24 | 1.3% | — |
| Q4 25 | 1.28× | — | ||
| Q3 25 | 1.90× | — | ||
| Q2 25 | 1.76× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.94× | — | ||
| Q3 24 | 2.05× | — | ||
| Q2 24 | 2.09× | — | ||
| Q1 24 | 1.72× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
HOLX
| Molecular Diagnostics | $255.3M | 24% |
| Breast Imaging | $219.9M | 21% |
| Services | $216.4M | 21% |
| Capital Equipment Componentsand Software | $187.2M | 18% |
| Cytology Perinatal | $76.0M | 7% |
| Interventional Breast Solutions | $71.2M | 7% |
| Blood Screening | $8.4M | 1% |
| Other Typeof Revenue | $5.4M | 1% |
WB
| Income from operations | $373.2M | 29% |
| Shares used in computing diluted net income per share attributable to Weibos shareholders | $268.1M | 21% |
| Shares used in computing basic net income per share attributable to Weibos shareholders | $238.6M | 19% |
| Value-added services | $186.1M | 14% |
| Less: Income tax expenses | $113.2M | 9% |
| Investment related income, net | $45.0M | 4% |
| Product development | $16.7M | 1% |
| General and administrative | $10.6M | 1% |
| Sales and marketing | $7.1M | 1% |
| Accretion to redeemable non-controlling interests | $3.0M | 0% |
